Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15303178 | 1.00 | KDM4E (0.32) | KDM4EMCOLN3NPSR1 | |
| SCHEMBL15303275 | 0.91 | NPSR1 (0.33) | KDM4EMCOLN3NPSR1 | |
| SCHEMBL15303678 | 0.91 | NPSR1 (0.33) | KDM4EMCOLN3NPSR1 | |
| SCHEMBL25053750 | 0.91 | NPSR1 (0.33) | KDM4EMCOLN3NPSR1 | |
| SCHEMBL15303677 | 0.91 | NPSR1 (0.33) | KDM4EMCOLN3NPSR1 | |
| SCHEMBL15303460 | 0.83 | AR (0.38) | KDM4EMCOLN3 | |
| SCHEMBL30939536 | 0.83 | AR (0.38) | KDM4EMCOLN3 | |
| SCHEMBL21116390 | 0.80 | KDM4E (0.31) | KDM4EMCOLN3 | |
| SCHEMBL9923889 | 0.76 | MMP13 (0.33) | KDM4EMCOLN3NPSR1 | |
| SCHEMBL9905745 | 0.76 | KEAP1 (0.48) | KDM4EMCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | KDM4E 1460/4885MCOLN3 288/4885NPSR1 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.